Abstract:Although the aetiology of Parkinson's disease (PD) and related neurodegenerative disorders is still unknown, recent evidence from human and experimental animal models suggests that a misregulation of iron metabolism, iron-induced oxidative stress and free radical formation are major pathogenic factors. These factors trigger a cascade of deleterious events leading to neuronal death and the ensuing biochemical disturbances of clinical relevance. A review of the available data in PD provides the following evidence in support of this hypothesis: (i) an increase of iron in the brain, which in PD selectively involves neuromelanin in substantia nigra (SN) neurons; (ii) decreased availability of glutathione (GSH) and other antioxidant substances; (iii) increase of lipid peroxidation products and reactive oxygen (O2)species (ROS); and (iv) impaired mitochondrial electron transport mechanisms. Most of these changes appear to be closely related to interactions between iron and neuromelanin, which result in accumulation of iron and a continuous production of cytotoxic species leading to neuronal death. Some of these findings have been reproduced in animal models using 6-hydroxydopamine, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), iron loading and beta-carbolines, although none of them is an accurate model for PD in humans. Although it is not clear whether iron accumulation and oxidative stress are the initial events causing cell death or consequences of the disease process, therapeutic efforts aimed at preventing or at least delaying disease progression by reducing the overload of iron and generation of ROS may be beneficial in PD and related neurodegenerative disorders. Current pharmacotherapy of PD, in addition to symptomatic levodopa treatment, includes 'neuroprotective' strategies with dopamine agonists, monoamine oxidase-B inhibitors (MAO-B), glutamate antagonists, catechol O-methyltransferase inhibitors and other antioxidants or free radical scavengers. In the future, these agents could be used in combination with, or partly replaced by, iron chelators and lazaroids that prevent iron-induced generation of deleterious substances. Although experimental and preclinical data suggest the therapeutic potential of these drugs, their clinical applicability will be a major challenge for future research.

Ion Channels and Metal Ions in Parkinson's Disease: Historical Perspective to the Current Scenario

Are ion channels potential therapeutic targets for Parkinson's disease?

Influence of heavy metals in Parkinson’s disease: an overview

Potassium Channels in Parkinson's Disease: Potential Roles in Its Pathogenesis and Innovative Molecular Targets for Treatment

The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease

Mechanistic Insights Expatiating the Redox-Active-Metal-Mediated Neuronal Degeneration in Parkinson's Disease

The Roles of Calcium Ions in Parkinson’s Disease: Calcium Channel Inhibitors as a Novel Agents?

Nanotechnology Driven Approaches for the Management of Parkinson's Disease: Current Status and Future Perspectives

Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs

Restoration of metal homeostasis: a potential strategy against neurodegenerative diseases

Interdependence of metals and its binding proteins in Parkinson’s disease for diagnosis

The role of iron transporters and regulators in Alzheimer's disease and Parkinson's disease: Pathophysiological insights and therapeutic prospects

Therapeutic Implications and Regulations of Protein Post-translational Modifications in Parkinsons Disease

Iron Deposition in Parkinson's Disease: A Mini-Review

Small Molecules in Parkinson's Disease Therapy: From Dopamine Pathways to New Emerging Targets

Epigenetic Modifications in Parkinson's Disease: A Critical Review

Parkinson's disease: From genetics to molecular dysfunction and targeted therapeutic approaches

A comprehensive review of natural compounds and their structure–activity relationship in Parkinson's disease: exploring potential mechanisms

Trends on Novel Targets and Nanotechnology-Based Drug Delivery System in the Treatment of Parkinson's disease: Recent Advancement in Drug Development

The Potential Role of Voltage-Dependent Anion Channel in the Treatment of Parkinson's Disease

Emerging Role of Plant-Based Bioactive Compounds as Therapeutics in Parkinson's Disease